Glp-1 receptor agonist compounds for sleep enhancement
AssigneeAmylin Pharmaceuticals, Inc.
InventorsJoseph T. Bass, Aaron D. Laposky, Fred W. Turek
Life of this patent
Estimating the term…
Abstract
The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to enhance sleep, increase the duration and/or intensity of non-rapid eye movement (NREM) sleep, treat NREM sleep disorders, and to treat circadian rhythm sleep disorders. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH2) and the like. In one embodiment, the GLP-1 receptor agonist compound is exenatide.
Claims43
A method to increase the duration of non-rapid eye movement sleep time in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to increase the duration of the non-rapid eye movement sleep time.
A method to increase the intensity of non-rapid eye movement sleep time in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to increase the intensity of the non-rapid eye movement sleep time.
A method to increase the duration and intensity of non-rapid eye movement sleep time in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to increase the duration and intensity of the non-rapid eye movement sleep time.
A method to increase the duration of uninterrupted non-rapid eye movement sleep time in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to increase the duration of the uninterrupted non-rapid eye movement sleep time.
A method to enhance sleep in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to enhance sleep.
A method to treat a non-rapid eye movement sleep disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat the non-rapid eye movement sleep disorder.
A method to treat sleepwalking disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat the sleepwalking disorder.
A method to treat sleep terror disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat the sleep terror disorder.
A method to treat enuresis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat enuresis.
A method to treat sleep bruxism in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat sleep bruxism.
A method to treat restless leg syndrome in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat restless leg syndrome.
A method to treat periodic limb movement disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat periodic limb movement disorder.
A method to treat a circadian rhythm sleep disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist compound or a pharmaceutical composition comprising a GLP-1 receptor agonist compound to treat the circadian rhythm sleep disorder.
The method of claim 19, wherein the circadian rhythm sleep disorder is desynchronosis.
The method of any one of claims 1-21, wherein the patient is human.
The method of claim 22, wherein the human is an adult.
The method of any one of claims 1-24, wherein the GLP-1 receptor agonist compound is an exendin, an exendin analog, GLP-1(7-37), or a GLP-1(7-37) analog.
The method of any one of claims 1-32, wherein the therapeutically effective amount of the GLP-1 receptor agonist compound is 0.01 μg to 5 mg.
The method of any one of claims 1-39, wherein the pharmaceutical composition comprises the GLP-1 receptor agonist compound, a preservative, a tonicity-adjusting agent and a buffer;
- and wherein the GLP-1 receptor agonist compound is exenatide.
The method of claim 42, wherein the biodegradable microspheres are poly(lactide-co-glycolide) microspheres.
The method of any one of claims 1-43, further comprising administering an effective amount of an amylin, an amylin analog, GIP, a GIP analog, PYY, a PYY analog, leptin, a leptin analog, or a combination of two or more thereof.
Dependencies are inferred from the claim text.